Protalix BioTherapeutics announced a collaboration with Secarna Pharmaceuticals to develop ASO therapies for rare renal indications. Protalix selected targets, and Secarna will use its OligoCreator platform to design ASO candidates. The agreement gives Protalix an option for exclusive licensing rights. Together, they aim to move programs from preclinical to clinical trials. PLX stock is up 2.78% in pre-market trading.

Read more at Nasdaq: Protalix, Secarna Partner To Develop ASO Treatments For Rare Renal Conditions